|
Author Archive: AZBio
NINDS Awards $150,000 Grant to NuvOx Pharma for Development of Field-ready Syringe for Oxygen Delivery Drug.
NuvOx Pharma, a clinical stage biotechnology company based in Tucson, Arizona, has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS). This grant will fund development of a novel syringe sonication device that may allow quick preparation of an investigational drug for oxygen delivery.Continue reading
HTG Molecular Diagnostics Expands its Collaboration with Merck KGaA, Darmstadt, Germany
Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research ProgramsContinue reading
Three Arizona Biotech Companies Win Fall Arizona Innovation Challenge
The Fall 2017 round of the Arizona Innovation Challenge (AIC) has concluded as the Arizona Commerce Authority (ACA) today announced six awardees in its semi-annual business plan competition including Arizona biotech companies Life365, Inc. GT Medical Technologies, and Resonea.
C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)
Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its first clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA) for the Symptoms of Major Depressive Disorder Scale (SMDDS). This qualification of the SMDDSfor exploratory use represents a major milestone for the PRO Consortium and specifically for the Depression Working Group, and is the culmination of a multi-year collaboration between FDA’s Center for Drug Evaluation and Research (CDER) and the PRO Consortium.Continue reading
Beacon Biomedical Inc. Announces the Launch of Its BeScreened™-CRC Test for Colorectal Cancer Screening
Phoenix, AZ.—Beacon Biomedical Inc., a medical diagnostic development company and CLIA laboratory based in Phoenix Arizona, today announced the launch of BeScreened™-CRC, a blood-based laboratory developed test (LDT) for colorectal cancer (CRC) screening that is 95% accurate at detecting CRC in adults ages 50-75 years of age with an overall 91% sensitivity and 86% specificity for CRC stages I-IV. Preliminary study findings also indicate a greater than 60% sensitivity for detecting precancerous polyps (advanced adenomas).Continue reading
Baylor Scott & White Research Institute and TGen Poised to Create Early Detection Test for Pancreatic Cancer
$5.13 million National Cancer Institute grant funds research to help identify patients before the disease causes symptoms or spreadsContinue reading
UA Project Tackles Challenge of Making Safer Melons
With funding from the U.S. Department of Agriculture, researchers will develop new disinfectants, grow new breeds of melons, and educate farmers, retailers and consumers on safe melon production practices.Continue reading
New imaging technology peers deep into the unfathomed 3D world of living single cells to advance disease diagnostics
Medical imaging technology like MRIs and CT scans have revolutionized the way patients are diagnosed with injuries and disease by enabling doctors to non-invasively look beneath the patient’s skin.